NO952336L - Insulin analoger - Google Patents

Insulin analoger

Info

Publication number
NO952336L
NO952336L NO952336A NO952336A NO952336L NO 952336 L NO952336 L NO 952336L NO 952336 A NO952336 A NO 952336A NO 952336 A NO952336 A NO 952336A NO 952336 L NO952336 L NO 952336L
Authority
NO
Norway
Prior art keywords
insulin analogues
analogues
resldle
hyperglycemic
ile
Prior art date
Application number
NO952336A
Other languages
English (en)
Other versions
NO952336D0 (no
Inventor
Ronald Eugene Chance
Li Fan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO952336D0 publication Critical patent/NO952336D0/no
Publication of NO952336L publication Critical patent/NO952336L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Analoger av humanlnsulln Inneholdende et Ala, Gly, Val, leu. Ile og Pro resldle l posisjon 26 til B-kJeden. og eventuelt, med modifikasjoner l andre posisjoner, utviser modifiserte fyslsk-kjemiske og farmakokinetlske egenskaper. Disse analogene er nyttige for behandling av hyperglyceml på grunn av at de er stabile og har liten tendens for selv-aggregering.
NO952336A 1992-12-18 1995-06-13 Insulin analoger NO952336L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99565992A 1992-12-18 1992-12-18
PCT/US1993/012237 WO1994014461A1 (en) 1992-12-18 1993-12-15 Insulin analogs

Publications (2)

Publication Number Publication Date
NO952336D0 NO952336D0 (no) 1995-06-13
NO952336L true NO952336L (no) 1995-06-13

Family

ID=25542078

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952336A NO952336L (no) 1992-12-18 1995-06-13 Insulin analoger

Country Status (14)

Country Link
EP (1) EP0605983A3 (no)
JP (1) JPH08504820A (no)
CN (1) CN1094059A (no)
AU (1) AU680462B2 (no)
BR (1) BR9307687A (no)
CA (1) CA2151134A1 (no)
CZ (1) CZ158895A3 (no)
FI (1) FI953001A0 (no)
HU (1) HUT71583A (no)
MX (1) MX9307991A (no)
NO (1) NO952336L (no)
PL (1) PL310007A1 (no)
WO (1) WO1994014461A1 (no)
ZA (1) ZA939477B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
SI3228320T1 (sl) 2008-10-17 2020-03-31 Sanofi-Aventis Deutschland Gmbh Kombinacija inzulina in agonista GLP-1
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
KR101983982B1 (ko) 2011-08-29 2019-05-30 사노피-아벤티스 도이칠란트 게엠베하 2형 당뇨병 환자의 혈당 조절에 사용하기 위한 약제학적 병용물
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CA2886228A1 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
MA41138B1 (fr) 2014-12-12 2023-07-31 Sanofi Aventis Deutschland Formulation à rapport fixe d'insuline glargine/lixisenatide
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
ZA924448B (en) * 1991-06-21 1993-12-17 Lilly Co Eli Insulin Analogs

Also Published As

Publication number Publication date
HUT71583A (en) 1995-12-28
FI953001A (fi) 1995-06-16
NO952336D0 (no) 1995-06-13
MX9307991A (es) 1994-08-31
AU680462B2 (en) 1997-07-31
HU9501762D0 (en) 1995-08-28
PL310007A1 (en) 1995-11-13
EP0605983A3 (en) 1995-06-07
CN1094059A (zh) 1994-10-26
BR9307687A (pt) 2002-02-19
WO1994014461A1 (en) 1994-07-07
FI953001A0 (fi) 1995-06-16
CA2151134A1 (en) 1994-07-07
EP0605983A2 (en) 1994-07-13
AU5827994A (en) 1994-07-19
CZ158895A3 (en) 1995-12-13
JPH08504820A (ja) 1996-05-28
ZA939477B (en) 1995-06-19

Similar Documents

Publication Publication Date Title
NO952336L (no) Insulin analoger
GEP20074095B (en) Analogs of human insulin modified at position 29 of the b chain thereof
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
AU2059088A (en) A device for the administration of implants
DE69332851D1 (de) Implantierbare, medizinische Eingriffsvorrichtung mit verstellbaren Kriterien zur Erkennung von Tachykardien
HUP9904023A2 (hu) Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban
DK203489A (da) Anti-t-celle receptor determinanter til diagnosticering og behandling af autoimmune sygdomme
ATE31625T1 (de) Pharmazeutisches mittel zur behandlung des diabetes mellitus.
BR9607647A (pt) Derivado de insulina e composição farmacêutica e processo para o tratamento de diabetes em um paciente em necessidade deste tratamento
DE69430868D1 (de) Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten
EP1234586A3 (en) Hepatoselective pharmaceutical actives
CS553490A3 (en) Transdermal therapeutic system
DK169784A (da) Peptider til farmaceutisk behandling af pattedyr
HK1002901A1 (en) A composition used as a therapeutic agent against chronic viral hepatic diseases
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
UA27102C2 (uk) Склад для стабілізації плазми крові у процесі пастеризації, спосіб пастеризації плазми крові і засіб для терапії препаратом плазми
FI913818A0 (fi) Nytt trombolytiskt aemne.
DK226889A (da) Alkoholpeptidderivat samt anvendelse deraf til mindskning af blodkoagulation
NO960545D0 (no) Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin
DK45990A (da) Peptid og middel indeholdende peptidet til farmaceutisk behandling af pattedyr
ES2142672T3 (es) Dispositivo de canula hipodermica flexible.
DK0495721T3 (da) Anvendelsen af et polypeptid med en humant-interleukin-2-aktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af pneumothorax
ES2101000T3 (es) Uso de bmy 14802 en el tratamiento de la ansiedad en pacientes con sindrome de abstinencia de benzodiazepinas.